ELC Group Expands into Pharmaceutical Product Development Market
News Jun 13, 2015
ELC Group has announced that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.
The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.
The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.
ELC Group selected the products based on a number of key criteria, including global market size, annual drug sales, prior experience, expertise, and therapeutic categories. Some of the products are being developed with very specific IP considerations and will qualify as Paragraph IV filings in the US, 505 b2 applications in the US, Hybrid applications in the EU, and first generics.
Commenting on the new product portfolio development, ELC Group CEO Marco Rubinstein said: “Our rapid growth, built on intense demand from our global customers, has meant that our business has been naturally moving towards this solution expansion for some time. We have some of the world’s leading experts working on the development of these products and we are keenly anticipating bringing them successfully to market in the near future.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018